Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.35 |
| ▸ | CDA | P32320 | 3/20 | 0.34 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.34 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | CD69 | Q07108 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14510444 | 0.89 | TK2 (0.37) | TK2CDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL21283066 | 0.89 | TK2 (0.37) | TK2CDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL23353386 | 0.89 | TK2 (0.37) | TK2CDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL21283173 | 0.81 | CDA (0.47) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL26798971 | 0.80 | CDA (0.39) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17929404 | 0.78 | CDA (0.34) | TK2CDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL24052323 | 0.77 | PRKCA (0.31) | — | |
| SCHEMBL24229287 | 0.74 | TK2 (0.62) | TK2 | |
| SCHEMBL50827 | 0.74 | TK2 (0.62) | TK2 | |
| SCHEMBL50826 | 0.74 | TK2 (0.62) | TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912779-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230287420-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230279395-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-11583591-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | AVIDITY BIOSCIENCES LLC (US) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583591-B2 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | MTPN, MYOF, TNNC1 | TK2 365/4885CDA 1663/4885SLC28A1 2756/4885 |
| US-20230279395-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MTPN, MYOF, CPT1B | TK2 607/4885CDA 986/4885SLC28A1 2758/4885 |
| US-11912779-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | MYOF, MTPN, PYGM | TK2 439/4885CDA 889/4885SLC28A1 3152/4885 |
| US-20230287420-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MTPN, MYOF, CPT1B | TK2 607/4885CDA 986/4885SLC28A1 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.